An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin and TB-500. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for easier access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how policymakers view custom-mixed peptide therapies, which have drawn increasing interest from consumers seeking alternatives to traditional drugs. Investigators say peptide treatments could alter approaches to stubborn infections, though concerns about safety persist. The committee's endorsement of four peptides paves the way for more expanded prescribing, even as skeptics warn of long-term evidence. Market watchers note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on some peptide candidates.